Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTX-301 Monotherapy and Combination in Advanced Solid Tumours
NCT04851834Phase 2Terminated
- Sponsor
- Xennials Therapeutics Inc.
- Start
- Aug 2021
- Primary completion
- Nov 2022
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of NTX-301 in solid tumor (advanced stage), ovarian cancer, bladder cancer, glioma, sponsored by Xennials Therapeutics Inc.. Started Aug 2021; status: terminated.
02
Drugs
NTX-301
03
Conditions
solid tumor (advanced stage)ovarian cancerbladder cancerglioma
Beyond the preview
Go deeper on NCT04851834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04851834.